Combined hormonal contraceptives and vitamin D metabolism in adolescent girls

Johanna Öberg1, Rolf Jorde1, Yngve Figenschau1,2, Per Medbøe Thorsby3, Sandra Rinne Dahl1, Anne Winther4 and Guri Grimnes1,5

1Tromso Endocrine Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromso, Norway
2Diagnostic Clinic, University Hospital of North Norway, Tromso, Norway
3Hormone Laboratory, Department of Medical Biochemistry and Biochemical Endocrinology and Metabolism Research Group, Oslo University Hospital, Aker, Oslo, Norway
4Division of Neurosciences, Orthopedics and Rehabilitation Services, University Hospital of North Norway, Tromso, Norway
5Division of Internal Medicine, University Hospital of North Norway, Tromso, Norway

Correspondence should be addressed to J Öberg: johanna.oberg@uit.no

This paper forms part of a special series on 100 Years of Vitamin D. The guest editors for this section were Josef Köhrle, Susan Lanham-New and Martina Rauner

Abstract

Objective: Combined hormonal contraceptive (CHC) use has been associated with higher total 25-hydroxyvitamin D (25(OH)D) levels. Here, we investigate the relation between CHC use and vitamin D metabolism to elucidate its clinical interpretation.

Methods: The cross-sectional Fit Futures 1 included 1038 adolescents. Here, a subgroup of 182 girls with available 25(OH)D, 1,25-dihydroxyvitamin D (1,25(OH)2D), 24,25-dihydroxyvitamin D (24,25(OH)2D), vitamin D-binding protein (DBP) and measured free 25(OH)D levels, in addition to parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), was investigated. Vitamin D metabolites were compared between girls using (CHC+) and not using CHC (CHC-). Further, the predictability of CHC on 25(OH)D levels was assessed in a multiple regression model including lifestyle factors. The ratios 1,25(OH)2D/25(OH)D and 24,25(OH)2D/25(OH)D (vitamin D metabolite ratio (VMR)) in relation to 25(OH)D were presented in scatterplots.

Results: CHC+ (n = 64; 35% of the girls) had higher 25(OH)D levels (mean ± s.d., 60.3 ± 22.2 nmol/L) than CHC- (n = 118; 41.8 ± 19.3 nmol/L), P-values <0.01. The differences in 25(OH)D levels between CHC+ and CHC- were attenuated but remained significant after the adjustment of lifestyle factors. CHC+ also had higher levels of 1,25(OH)2D, 24,25(OH)2D, DBP and calcium than CHC-, whereas 1,25(OH)2D/25(OH)D, PTH, FGF23 and albumin were significantly lower. Free 25(OH)D and VMR did not statistically differ, and both ratios appeared similar in relation to 25(OH)D, irrespective of CHC status.

Conclusion: This confirms a clinical impact of CHC on vitamin D levels in adolescents. Our observations are likely due to an increased DBP-concentration, whereas the free 25(OH)D appears unaltered.
**Introduction**

In the adult population, hormonal contraceptive (HC) use has been associated with increased total 25-hydroxyvitamin D (25(OH)D) levels (1, 2, 3), but few studies have assessed this in adolescents (4). As HC use in this age group is quite common in some countries, including Norway (5), it is important to understand how such use affects vitamin D metabolism, and how to interpret 25(OH)D measurements in this population. The effect of HC use on 25(OH)D levels is so far not accounted for in existing guidelines (6, 7, 8, 9).

In contrary to 25(OH)D (free and protein bound), free 25(OH)D has not differed according to HC use in the adult population (3, 10). It has been raised concern that the vitamin D status in HC users might be over-estimated, as many cells utilize free 25(OH)D (10). As such, free 25(OH)D could represent a more useful marker of vitamin D status in an HC using population.

Also, an increase in vitamin D-binding protein (DBP) in users of combined hormonal contraceptives (CHC), which includes an estrogenic component, has been consistently reported (3, 11). Several tissues, including the parathyroid gland, can utilize DBP-bound 25(OH)D (12), but not detected; hence, vitamin D will be measured and a relatively long half-life compared to the other vitamin D metabolites (13, 14). However, to correctly interpret 25(OH)D levels in CHC users, other metabolites in the vitamin D pathway might be useful. Also, 1,25(OH)2D/25(OH)D and vitamin D metabolite ratio defined by 24,25(OH)D3/25(OH)D (VMR) have been suggested as alternatives to 25(OH)D measurements (15, 16).

The aim of this study was therefore to compare 25(OH)D, 1,25(OH)2D, 24,25(OH)2D, DBP, free 25(OH)D, 1,25(OH)2D/25(OH)D, VMR, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), according to CHC use in adolescents. Further, we wanted to investigate if CHC use was an independent predictor of 25(OH)D levels when accounting for other lifestyle factors. Finally, we wanted to explore whether the ratios 1,25(OH)2D/25(OH)D and VMR in relation to 25(OH)D differed by CHC use, presented in scatterplots.

**Methods**

**Study population**

Fit Futures is a population-based, longitudinal study of the transition from adolescence to adulthood ongoing in Tromsø and Balsfjord municipality in North Norway (69°N). Fit Futures 1 was performed at The Research Unit at the University Hospital in North Norway, from September 2010 to April 2011, with 1038 attendees (girls n = 508) in their first year of upper secondary school (92.9% attendance rate), >95% were of Caucasian ethnicity. All participants gave their written consent prior to the study; for those under 16 years old, additional consent from a parent/proxy was required. The Regional Committee for Medical and Health Research Ethics North Norway and The Norwegian Data Protection Authority approved the study (2011/1684/REC North). Further study characteristics are accessible elsewhere (17).

We included a subsample of 182 girls from Fit Futures 1, whose stored serum samples were analyzed for 1,25(OH)2D, 24,25(OH)2D, DBP and FGF23 in 2016, free 25(OH)D in 2020, in addition to the 25(OH)D and PTH measured in 2012/2011. All participants <19 years with 25(OH)D levels ≥70 nmol/L or <20 nmol/L were included. In addition, a random sample of 25 individuals from each 10 nmol/L groups (20–29, 30–39, 40–49, 50–59 and 60–69 nmol/L) was selected (Table 1). If the selected participant lacked available serum (n = 1), the participant was excluded and not replaced. The selection process was designed to cover the whole range of 25(OH)D levels within available financial frames. 25(OH)D3 was measured simultaneously, but not detected; hence, vitamin D will refer to 25(OH)D3 (17).

**Questionnaire**

The participants filled out a questionnaire regarding various health aspects. To categorize participants into

**Table 1** Selection process of subsample from Fit Futures 1.

| Girls available for primary (original) analysis (≤18 years and available serum sample): n = 415. | 25(OH)D, nmol/L | Original sample | Subsample |
|---|---|---|---|
| <10 | 0 | 0 |
| 10–20 | 22 | 22 |
| 20–30 | 78 | 25 |
| 30–40 | 96 | 25 |
| 40–50 | 77 | 25 |
| 50–60 | 62 | 25 |
| 60–70 | 44 | 24 |
| 70–80 | 19 | 19 |
| 80–90 | 14 | 14 |
| 90–100 | 1 | 1 |
| 100–110 | 2 | 2 |
| Total | 415 | 182 |

25(OH)D, 25-hydroxyvitamin D.
using (CHC+) or not using (CHC−) CHC, questions regarding contraceptive use were utilized. Images of HC products including brand names, were shown to aid participants recalling the name of their contraceptive. Sexual maturation was assessed by using age of menarche to divide the participants into early (<12.5 years), intermediate (12.5–14 years) and late (>14 years) sexual maturation. Age was measured in years.

In addition, we included the following variables regarding lifestyle and skin type: smoking and snuff habits, intake of fatty fish, cod liver and roe ‘mølje’, semi-skimmed milk (fortified with 0.4 µg vitamin D per 100 g), cod liver oil, vitamin/mineral supplements, screen time in weekends, physical activity, skin type according to sun sensitivity, sunbathing holiday and use of solarium.

For use in statistical analyses, some categorical answer options had to be merged due to low numbers of respondents: ‘Do you smoke’? (No/never, sometimes, daily); alternatives ‘sometimes’ and ‘daily’ were merged into ‘sometimes or daily’, ‘How often do you usually eat fat fish (e.g. salmon, trout, mackerel and herring)’ (Rarely/never, one to three times per month, one to three times per week, four to six times per week, every day); alternatives ‘one to three times per week’ , ‘four to six times per week’ and ‘every day’ were merged into ‘weekly fish’, ‘How often do you usually eat cod liver and roe (mølje)’? (Rarely/never, one to six glasses per week, one glass per day, two to three glasses per day, four or more glasses per day); alternatives ‘two to three glasses per day’ and ‘four or more glasses per day’ were merged into ‘more than one glass per day’, ‘How does your skin react to sunbathing in the summer?’ (Always red never brown, ‘one to three times per week’ , ‘four to six times per week’ and ‘every day’ were merged into ‘weekly fish’, ‘How often do you usually eat fat fish (e.g. salmon, trout, mackerel and herring)’ (Rarely/never, one to three times per month, one to three times per week, four to six times per week, every day); alternatives ‘one to three times per week’ , ‘four to six times per week’ and ‘every day’ were merged into ‘weekly fish’, ‘How often do you usually eat cod liver and roe (mølje)’? (Rarely/never, one to six glasses per week, one glass per day, two to three glasses per day, four or more glasses per day); alternatives ‘two to three glasses per day’ and ‘four or more glasses per day’ were merged into ‘more than one glass per day’, ‘How does your skin react to sunbathing in the summer?’ (Always red never brown, almost always red sometimes brown, almost always brown sometimes red, always brown); alternatives ‘always red, never brown’ and ‘almost always red, sometimes brown’ were merged into ‘mostly red’.

**Laboratory analyses**

Non-fasting blood samples were collected at the study site in 2010/2011 and stored in the Biobank at the UiT The Arctic University of Norway, at −70°C. Samples from the entire cohort (n = 890) were analyzed for 25(OH)D at the Hormone Laboratory, Haukeland University Hospital, Bergen, Norway by high-pressure liquid chromatography mass spectroscopy (LC-MS/MS), total analytical variation (CVa) was 10%. A selection of the samples was reanalyzed for 25(OH)D at University College Cork, Cork, Ireland, by LC-MS/MS, as a part of the International Vitamin D Standardization Program (VDSP). Further, a statistical regression equation was applied to the remaining 25(OH)D measurements to achieve standardized serum 25(OH)D values according to VDSP protocol, R² between the original 25(OH)D measurements and the standardized 25(OH)D measurements was 0.98 (18). The standardized values were applied here.

1,25(OH)₂D was analyzed by enzyme immunoassay (CVa 14% at 55 pmol/L and 82 pmol/L; 13% at 152 pmol/L), 24,25(OH)₂D by LC-MS/MS (no coefficient of variation (CV) available) and DBP by RIA, (CVa 10% at 3.2 µmol/L and 6.2 µmol/L), using polyclonal antibodies. These analyses were performed at the Hormone Laboratory at Oslo University Hospital, Oslo, Norway, which participates in Vitamin D external quality assessment for 1,25(OH)₂D measurements. The lower limit of detection of 24,25(OH)₂D was 20 nmol/L, hence all participants with values under this limit were allocated the value 0 (n = 27).

Serum free 25(OH)D was analyzed by a competitive ELISA assay, cat. no. KAPF 1991, DIAsource ImmunoAssays SA (Louvain-la-Neuve, Belgium) DIAsource – Vitamin D (diaSource-diagnostics.com), accessed on February 8, 2022. The assay had an intermediate precision of ≤ 6.3% (CV) as tested at four concentrations ranging from 14.5 to 70.1 pmol/L. FGF23 (intra CV 9%, inter CV 26%), was analyzed by immunoassay at OLINK® Proteomics, Uppsala, Sweden, and reported in Normalized Protein eXpression (NPX) values (log2 scale). Serum PTH, calcium and albumin were analyzed at the Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway. PTH was analyzed by an electrochemiluminescence immunoassay using an automated clinical chemistry analyser, Cobas® 6000, Roche Diagnostics. The laboratory used Quality Management from Tieto Enator (Helsinki, Finland) (CVa of 6.4, 3.7 and 4.6% at 1.9, 3.4 and 10.1 pmol/L, respectively) for PTH measurements. Calcium was analyzed by photometry using an automated clinical chemistry analyser, Cobas® 8000, Roche Diagnostics. CVa was 1.35% at 2.37 mmol/L. Likewise, albumin was analyzed by the Cobas® 8000, CVa was 1.4% at 45.0 g/L.

**Physical measurements**

Anthropometric measures in light clothing and without shoes included height measured to the nearest cm and
weight to the nearest hectogram. BMI was calculated by weight (kg)/height (m)².

**Statistics**

All statistical calculations were performed using IBM SPSS statistics version 25 (IBM Corp. Released 2017. IBM SPSS statistics for Windows, Version 25.0.: IBM Corp.) Normality of the data was judged by visual inspection of histogram and Q-Q plot. Homoscedasticity was assessed by residual plot and linearity by scatterplot. All tests were two-tailed, and a P-value < 0.05 was considered statistically significant.

There was one extreme outlier (92.4 pmol/L) present in the free 25(OH)D measurements, which was removed from the analysis. Due to many participants with undetectable 24,25(OH)₂D concentrations, we reported this metabolite as a percentage of participants with undetectable 24,25(OH)₂D values in each category.

25(OH)D levels were categorized consistent with international guidelines: <30, 30–50, 50–75 and >75 nmol/L (6, 7). ANOVA was used to calculate means and to assess weighted linear trends across vitamin D categories.

Vitamin D metabolites were compared between CHC+ and CHC- by chi-square test for categorical variables and t-tests for continuous variables. Similarly, lifestyle and biological variables included in previous analyses in the complete Fit Futures cohort (17), were compared between CHC+ and CHC-. Lifestyle variables significantly different between the groups in univariate analyses were further included in multiple regression analyses together with age, BMI and CHC status with 25(OH)D as a dependent variable.

A Lowess curve was fitted to the observations of 1,25(OH)₂D/25(OH)D and VMR in relation to 25(OH)D levels in a scatterplot, stratified by CHC status.

**Results**

Fit Futures 1 included 415 eligible girls, where 182 met the selection criteria for this study (Table 1). The median age was 16 years with a mean ± s.d. BMI of 22.3 ± 4.0 kg/m². Mean ± s.d. 25(OH)D was 48.3 ± 22.1 nmol/L with corresponding PTH at 3.9 ± 1.3 pmol/L. Of the participants, 64 (35%) were CHC+. Table 2 demonstrates the baseline characteristics and biological variables across 25(OH)D categories. CHC+ were overrepresented in the highest categories, constituting 74.1% of the participants with 25(OH)D >75 nmol/L. There were significant linear increasing levels of 1,25(OH)₂D, 24,25(OH)₂D, DBP, free 25(OH)D and decreasing levels of PTH across the 25(OH)D categories (Table 2). In participants with 25(OH)D levels <30 nmol/L, 44.7% of 24,25(OH)₂D levels were undetectable, while all participants with 25(OH)D >75 nmol/L had detectable 24,25(OH)₂D values (Table 2).

In univariate models, CHC+ were more likely to use snuff, vitamin/mineral supplements, and solarium and less likely to eat fatty fish (Table 3). Further, the differences in 25(OH)D levels between CHC+ and CHC- were significant (60.3 ± 22.2 and 41.8 ± 19.3 nmol/L, respectively, P < 0.01). CHC+ also had higher levels of 1,25(OH)₂D,

---

**Table 2** Results from ANOVA analysis: baseline characteristics, vitamin D metabolites, PTH, FGF23 and calcium according to categories of 25(OH)D levels.

| 25(OH)D, nmol/L | <30 | 30–50 | 50–75 | >75 | P-value for linear trend |
|-----------------|-----|-------|-------|-----|-------------------------|
| Baseline characteristics |     |       |       |     |                         |
| Number of persons (n) | 44  | 48    | 53    | 26  | n.a                     |
| CHC+ (%) | 17.0 | 28.0  | 37.9  | 74.1 | <0.001                   |
| BMI (kg/m²) | 22.5 ± 4.7 | 23.2 ± 4.7 | 21.8 ± 3.4 | 21.2 ± 2.2 | 0.091                  |
| Biological variables |     |       |       |     |                         |
| 1,25(OH)₂D (nmol/L) | 98.2 ± 31.0 | 119.0 ± 38.4 | 124.4 ± 33.0 | 148.4 ± 66.2 | <0.001                  |
| 24,25(OH)₂D (nmol/L) | 21.1 ± 21.0 | 39.6 ± 22.4 | 62.2 ± 32.5 | 79.0 ± 36.3 | <0.001                  |
| 24,25(OH)₂D percentage below limit of detection | 44.7% | 10.0%  | 1.7%  | 0%  | n.a                     |
| DBP (µmol/L) | 3.5 ± 0.7 | 3.6 ± 0.7 | 4.0 ± 0.9 | 4.6 ± 1.3 | <0.001                  |
| Free 25(OH)D (pg/mL) | 5.6 ± 3.9 | 7.2 ± 3.7 | 8.6 ± 4.9 | 8.5 ± 3.5 | <0.001                  |
| PTH (pmol/L) | 4.3 ± 1.5 | 4.0 ± 1.5 | 3.6 ± 0.9 | 3.5 ± 1.1 | 0.004                   |
| FGF23, NPX values | 2.8 ± 0.9 | 2.8 ± 1.0 | 2.5 ± 0.6 | 2.6 ± 0.7 | 0.073                   |
| Calcium (mmol/L) | 2.30 ± 0.1 | 2.30 ± 0.1 | 2.31 ± 0.1 | 2.30 ± 0.1 | 0.834                   |
| Albumin (g/L) | 45.0 ± 2.7 | 44.0 ± 2.4 | 45.0 ± 2.3 | 43.6 ± 3.0 | 0.191                   |

CHC+, combined hormonal contraceptive users; DBP, vitamin D-binding protein; free 25(OH)D, measured free 25(OH)D; FGF23, fibroblast growth factor; PTH, parathyroid hormone; 1,25(OH)₂D, 1,25-dihydroxyvitamin D; 24,25(OH)₂D, 24,25-dihydroxyvitamin D.
Table 3  Results from Pearson's chi-square test of categorical variables and CHC use.

| Categorical variables                                      | CHC+ | CHC−  | Pearson's chi-square, \( P \)-value |
|------------------------------------------------------------|------|-------|-----------------------------------|
| Lifestyle variables                                        |      |       |                                   |
| Smoking status                                             |      |       |                                   |
| Never                                                      | 46 (73.0) | 93 (80.9) | 0.226                             |
| Sometimes or daily                                         | 17 (27.0) | 22 (19.1) |                                   |
| Snuff use                                                  |      |       |                                   |
| Never                                                      | 24 (38.1) | 86 (74.1) | <0.001                            |
| Sometimes                                                  | 16 (25.4) | 14 (12.1) |                                   |
| Daily                                                      | 23 (36.5) | 16 (13.8) |                                   |
| Fatty fish intake                                          |      |       |                                   |
| Rarely/never                                               | 13 (20.6) | 19 (16.4) | 0.010                             |
| One to three times per month                               | 42 (66.7) | 58 (50.0) |                                   |
| Weekly fish                                                | 8 (12.7) | 39 (33.6) |                                   |
| Cod liver and roe 'Mølje' intake                           |      |       |                                   |
| Rarely/never                                               | 42 (66.7) | 70 (60.3) | 0.706                             |
| 1–3 times per year                                         | 15 (23.8) | 33 (28.4) |                                   |
| 4 or more times per year                                   | 6 (9.5) | 13 (11.2) |                                   |
| Extra semi-skimmed milk intake                             |      |       |                                   |
| Rarely/never                                               | 32 (50.8) | 44 (37.9) | 0.202                             |
| 1–6 glasses per week                                       | 15 (23.8) | 29 (25.0) |                                   |
| 1 glass per day                                            | 8 (12.7) | 29 (25.0) |                                   |
| >1 glass per day                                           | 8 (12.7) | 14 (12.1) |                                   |
| Cod liver oil intake                                       |      |       |                                   |
| No                                                         | 31 (49.2) | 57 (49.6) | 0.636                             |
| Sometimes                                                  | 22 (34.9) | 34 (29.6) |                                   |
| Daily                                                      | 10 (15.9) | 24 (20.9) |                                   |
| Vitamin/mineral supplements intake                         |      |       |                                   |
| No                                                         | 12 (19.0) | 46 (39.7) | 0.016                             |
| Sometimes                                                  | 33 (52.4) | 49 (42.2) |                                   |
| Daily                                                      | 18 (28.6) | 21 (18.1) |                                   |
| Screen time weekends                                       |      |       |                                   |
| 0–1.5 h                                                    | 11 (17.5) | 18 (15.5) | 0.584                             |
| 2–3 h                                                      | 19 (30.2) | 47 (40.5) |                                   |
| 4–6 h                                                      | 24 (38.1) | 36 (31.0) |                                   |
| >7 h                                                       | 9 (14.3) | 15 (12.9) |                                   |
| Physical activity in leisure time                          |      |       |                                   |
| Sedentary                                                  | 9 (14.3) | 12 (10.3) | 0.827                             |
| ≥4 h a week                                                | 26 (41.3) | 49 (41.9) |                                   |
| Recreational sports                                        | 16 (25.4) | 35 (29.9) |                                   |
| Hard training                                              | 12 (19.0) | 21 (17.9) |                                   |
| Sunbathing holiday last 2 months                           |      |       |                                   |
| No                                                         | 55 (87.3) | 107 (92.2) | 0.282                             |
| Yes                                                        | 8 (12.7) | 9 (7.8) |                                   |
| Solarium use last 4 weeks                                  |      |       |                                   |
| No                                                         | 26 (41.3) | 84 (72.4) | <0.001                            |
| Yes                                                        | 37 (58.7) | 32 (27.6) |                                   |
| Biological variables                                       |      |       |                                   |
| Puberty status                                             |      |       |                                   |
| Early                                                      | 28 (45.9) | 40 (34.5) | 0.186                             |
| Intermediate                                               | 18 (29.5) | 50 (43.1) |                                   |
| Late                                                       | 15 (24.6) | 26 (22.4) |                                   |
| Skin type according to sun sensitivity                     |      |       |                                   |
| Mostly red                                                 | 11 (17.7) | 23 (20.0) | 0.774                             |
| Almost always brown, sometimes red                         | 39 (62.9) | 66 (57.4) |                                   |
| Always brown, never red                                    | 12 (19.4) | 26 (22.6) |                                   |

CHC+, combined hormonal contraceptive users; CHC−, combined hormonal contraceptive non-users.
Table 4: Results from t-tests on continuous variables by CHC use. Mean values ± s.d. adjusted for BMI and age.

| Number of persons (n) | CHC+       | CHC–       | t-Test, P-value |
|-----------------------|------------|------------|----------------|
| 25(OH)D (nmol/L)      | 64         | 117        | 0.001          |
| 1,25(OH)D (pmol/L)    | 128.1 ± 48.2 | 115.2 ± 39.9 | 0.042         |
| 24,25(OH)D (nmol/L)   | 61.9 ± 37.6 | 40.4 ± 30.2 | <0.001        |
| DBP (µmol/L)          | 4.5 ± 1.0  | 3.4 ± 0.7  | <0.001        |
| Free 25(OH)D (pg/mL)  | 7.7 ± 4.6  | 7.3 ± 4.1  | 0.603         |
| 1,25(OH)D/25(OH)D     | 2.4 ± 1.2  | 3.4 ± 1.9  | <0.001        |
| VMR                   | 1.1 ± 0.6  | 1.0 ± 0.7  | 0.374         |
| PTH (pmol/L)          | 3.6 ± 1.1  | 4.1 ± 1.4  | 0.035         |
| FGF23, NPX values     | 2.5 ± 0.8  | 2.8 ± 0.8  | 0.023         |
| Calcium (mmol/L)      | 2.30 ± 0.1 | 2.27 ± 0.1 | 0.005         |
| Albumin (g/L)         | 43.2 ± 2.6 | 45.1 ± 2.4 | <0.001        |

CHC+, combined hormonal contraceptive users; DBP, vitamin D-binding protein; free 25(OH)D, measured free 25(OH)D; FGF23, fibroblast growth factor; PTH, parathyroid hormone; VMR, 24,25-dihydroxyvitamin D vitamin D metabolite ratio; 2325(OH)D, 25-hydroxyvitamin D; 1,25(OH)D, 1,25-dihydroxyvitamin D; 24,25(OH)D, 24,25-dihydroxyvitamin D.

24,25(OH)D2, DBP and calcium than CHC–, whereas 1,25(OH)D2/25(OH)D, PTH, FGF23 and albumin were significantly lower. There were no differences in free 25(OH)D and VMR levels (Table 4).

The multiple regression model included the categorical variables that differed according to CHC use in univariate models (snuff habits, intake of fatty fish, vitamin/mineral supplement intake and solarium use), in addition to age, BMI and CHC status. Adjustment for these variables attenuated, but did not remove, the differences in 25(OH)D levels between CHC+ and CHC–. Solarium and CHC use significantly predicted an increase in 25(OH)D levels by unstandardized B (95% CI) of 20.7 (15.0–26.4) and 9.7 (3.5–16.0) nmol/L, respectively. BMI, age, snuff habits, intake of fatty fish and vitamin/mineral supplement intake did not contribute significantly to the model. The model explained 37.6% of the variation in 25(OH)D levels (Table 5).

By visualizing 1,25(OH)D2/25(OH)D and VMR in relation to 25(OH)D in scatterplots, there was no clear differences in the patterns of observations according to CHC status (Figs 1A, B and 2A, B).

Discussion

This study reports a marked significant difference in 25(OH)D levels according to CHC use among adolescent girls, the difference remained, but was attenuated after adjustment for lifestyle variables. The higher 25(OH)D levels were congruent with higher 1,25(OH)D2, 24,25(OH)D2, DBP and calcium while 1,25(OH)D2/25(OH)D, PTH, FGF23 and albumin were lower. Free 25(OH)D and VMR did not differ, also there were no differences in the patterns of 1,25(OH)D2/25(OH)D and VMR in relation to 25(OH)D levels, stratified by CHC use.

Differences in 25(OH)D levels according to estrogen use in women, both postmenopausal and in childbearing age (>18 years) is well described in previous publications (1, 2, 3, 19). However, studies on 25(OH)D levels in the CHC using adolescent population are scarce. In this study of adolescent girls, the difference between CHC+ and CHC– in 25(OH)D levels was profound, constituting almost 20 nmol/L in univariate analyses, consistent with findings in 16–25 years old Australian girls (4). Of note, differences in solarium use explained half the difference in our population.

Increased DBP and 25(OH)D levels in CHC users have been previously reported (3, 20), and is considered due to the estrogen component in CHC stimulating the hepatic production of DBP; as is the case for many binding globulins (21, 22). As approximately 90% of 25(OH)D is bound to DBP, this carrier protein clearly has an important role in maintaining 25(OH)D levels (23, 24). This point was further demonstrated in a patient lacking DBP; with almost
undetectable 25(OH)D levels (25). In addition, progestins may affect DBP levels (20), also in line with other globulins (21). DBP concentration and binding affinity have genetic variation, with different ethnic distributions (23); however, as the majority of our study participants are of Caucasian ethnicity, we do not believe this will largely impact our findings. Previous studies have reported lower albumin levels in women taking exogenous estrogen, in line with our findings (26, 27).

There was a linearly increasing trend of free 25(OH)D across 25(OH)D categories. However, free 25(OH)D levels did not differ according to CHC use in line with previous studies in the adult population (3, 10). Due to its bioavailability and proposed independence of DBP levels, free 25(OH)D has been suggested as a marker of vitamin D status, as a replacement for or in addition to 25(OH)D measurements (12, 28). This relates to the free hormone hypothesis, stating that the concentration of free hormone in serum controls the concentration of hormone inside the cell, and thus the biological activity (12, 29). However, the true availability of free hormone to the cell depends on numerous factors, including blood flow, serum concentrations, the type and amount of binding proteins and their dissociation constants, cellular uptake and intracellular elimination (29). One could speculate that an unknown active regulation of any of these steps contributes to maintain a stable free 25(OH)D concentration irrespective of CHC use.

It has been argued that the equal levels of free 25(OH)D could mean an over-estimation of vitamin D status based on 25(OH)D levels in HC users (10). However, DBP-bound 25(OH)D can be utilized by cells which has the membrane-anchored megalin/cubulin-complex, as do the kidneys and the parathyroid gland (30), consistent with the lower PTH and higher calcium levels in the CHC+. In fact, in our population, the difference in free calcium could be expected to be even larger, as albumin was lower in CHC+, however, this was not measured. In addition to the megalin/cubulin-complex, there might be other receptors making DBP-bound 25(OH)D available to cells (12, 31).

The lower PTH and higher calcium could represent clinically relevant differences in 25(OH)D levels according to CHC use, at least in a bone health perspective. This supports previous studies, concluding that 25(OH)D is still the metabolite of choice regarding the effect of vitamin D on bone health (32, 33), although one study reported superior correlations of free 25(OH)D (34).

We investigated possible confounding variables on 25(OH)D levels. In univariate analysis, CHC+ differed in snuff habits, fatty fish intake, vitamin/mineral supplement...

Figure 1
(A) Scatterplot of 1,25(OH)2D/25(OH)D in relation to 25(OH)D in CHC−. (B) Scatterplot of 1,25(OH)2D/25(OH)D in relation to 25(OH)D in CHC+.

Figure 2
(A) Scatterplot of VMR in relation to 25(OH)D in CHC−. (B) Scatterplot of VMR in relation to 25(OH)D in CHC+.
intake and solarium use. These lifestyle habits can influence 25(OH)D levels and was, therefore, included in the multiple regression model together with BMI, age and CHC. Here, solarium and CHC use were significant predictors of higher 25(OH)D levels. This confirms that UV exposure is a strong predictor of 25(OH)D levels in this cohort, as previously published (17).

Both 1,25(OH)2D/25(OH)D and VMR have been suggested as alternative markers of vitamin D status due to their close relation to 25(OH)D levels (16, 35). Although the 1,25(OH)2D/25(OH)D ratio was higher in CHC- than CHC+, the distribution of the ratio across 25(OH)D levels was similar in both groups. The VMR was not statistically different according to CHC use, and the scatterplots were comparable. These results indicate a similar vitamin D metabolite regulation, irrespective of CHC use.

Although this study was based on a selected young population according to their 25(OH)D levels, the results of this study are relevant for a female adolescent population, at least of Caucasian origin. We had the opportunity to investigate vitamin D metabolism in an adolescent population ranging from deficiency to sufficient vitamin D levels. In addition, the 25(OH)D measurements were standardized according to VDSP. Another strength of the study is that we measured free 25(OH)D, which provides more accurate values than those obtained by calculating levels based on measured 25(OH)D, albumin and DBP (36, 37, 38). Although the use of CHC was self-reported, the information was confirmed through interviews using images to ensure the correct brand names. A limitation is the number of participants. Also, we did not have information regarding the length of CHC use. Last, although we included many variables related to 25(OH)D levels, we cannot exclude unmeasured confounders influencing the effect of CHC on 25(OH)D levels. Further research is needed to establish the long-term effects of CHC use and the effect of cessation of CHC on vitamin D levels, which is important from a clinical point of view.

In conclusion, this study confirms the impact of CHC use on vitamin D levels in an adolescent population, which could be clinically relevant due to corresponding differences in calcium and PTH levels. The 25(OH)D levels in CHC+ therefore seem to represent a valid measure of the vitamin D status in this population.

Declaration of Interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
12 Chun RE, Peery BE, Orwell ES, Nielsom CM, Adams JS & Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. Journal of Steroid Biochemistry and Molecular Biology 2014 144 132–137. (https://doi.org/10.1016/j.jsbmb.2013.09.012)

13 Giustina A, Adler RA, Binkley N, Bollerslev J, Bouillon R, Dawson-Hughes B, Ebeling PR, Feldman D, Formenti AM, Lazaretti-Castro M, et al. Consensus statement from 2(nd) International Conference on controversies in vitamin D. Reviews in Endocrine and Metabolic Disorders 2020 21 89–116. (https://doi.org/10.1007/s11154-019-09532-w)

14 Prentice A, Goldberg GR & Schoenmakers I. Vitamin D across the lifecycle: physiology and biomarkers. American Journal of Clinical Nutrition 2008 88 5005–5065. (https://doi.org/10.1093/ajcn/88.2.5005)

15 Ginsberg C, Katz R, de Boer IH, Kestenbaum B, Siscovick DS, et al. The 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: the cardiovascular health study. Bone 2018 107 124–130. (https://doi.org/10.1016/j.bone.2017.11.011)

16 Pasquali M, Tartaglione L, Rotondi S, Muci ML, Gandanici G, Farcomeni A, Marangella M & Mazzaferrro S. Calcitriol/calcidiol ratio: an indicator of vitamin D hydroxilation efficiency? BBA Clinical 2015 3 251–256. (https://doi.org/10.1016/j.bacl.2015.03.004)

17 Oberg J, Jorde L, Almas B, Emaus N & Grimes G. Vitamin D deficiency and lifestyle risk factors in a Norwegian adolescent population. Scandinavian Journal of Public Health 2014 42 593–602. (https://doi.org/10.1177/0301200514541593)

18 Cashman KD, Dowlings KG, Bollerslev J, Bovill R, Dawson-Hughes B, Ebeling PR, Feldman D, Formenti AM, Lazaretti-Castro M, et al. Consensus statement from 2(nd) International Conference on controversies in vitamin D. Reviews in Endocrine and Metabolic Disorders 2020 21 89–116. (https://doi.org/10.1007/s11154-019-09532-w)

19 Bansal N, Katz R, de Boer IH, Kestenbaum B, Siscovick DS, Almas B, Emaus N & Grimes G. Vitamin D deficiency and lifestyle risk factors in a Norwegian adolescent population. Scandinavian Journal of Public Health 2014 42 593–602. (https://doi.org/10.1177/0301200514541593)

20 Stanczyk FZ, Stripera I, Danis R, Pandian R, Matharu H, Bender N & Nativo M. Effect of oral contraceptives on total and bioavailable 25-hydroxyvitamin D. Journal of Steroid Biochemistry and Molecular Biology 2021 211 108979. (https://doi.org/10.1016/j.jsbmb.2021.108979)

21 Wiegmann I, Kutschera E, Lee JH, Moore C, Mellingner U, Winkler UH & Kuhl E. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003 67 25–32. (https://doi.org/10.1016/S0010-7824(02)00436-5)

22 Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, Hoofnagle AN, Rifkin DE, Garimella PS, et al. Vitamin D-binding protein deficiency and homozygous deletion of the GC Gene. New England Journal of Medicine 2019 380 1150–1157. (https://doi.org/10.1056/NEJMoa1807841)

23 Chun RE, Peery BE, Orwell ES, Nielsom CM, Adams JS & Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. Journal of Steroid Biochemistry and Molecular Biology 2014 144 132–137. (https://doi.org/10.1016/j.jsbmb.2013.09.012)

24 Bikle DD, Gee E, Halloran B, Moe OW & Sakkaee K. Effects of sex and postmenopausal estrogen use on serum phosphorus levels: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2003–2006. American Journal of Kidney Diseases 2014 63 198–205. (https://doi.org/10.1016/j.jakd.2013.07.012)

25 Bille DD, Malmstrom S & Schwartz J. Current controversies: are free vitamin metabolite levels a more accurate assessment of vitamin D status than total levels? Endocrinology and Metabolism Clinics of North America 2017 46 901–918. (https://doi.org/10.1016/j.ecl.2017.07.013)

26 Mendel CM. The free hormone hypothesis. Distinction from the free hormone transport hypothesis. Journal of Andrology 1992 13 107–116.

27 Lundgren S, Carlberg T, Hjalmar C, Rastad J, Pihlgren U, Rask L, Akerstrom G & Hellman P. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. Journal of Histochemistry and Cytochemistry 1997 45 383–392. (https://doi.org/10.1177/002215549704500306)

28 Michaelsson K, Rasmusson A, Wolk A, Byberg L, Mitchell A & Melhus H. The free hormone hypothesis: is free serum 25-hydroxyvitamin D a better marker for bone mineral density in older women? JBM Plus 2018 2 367–374. (https://doi.org/10.1002/jbpm.10059)

29 Alola J, Dhaliwal R, Mikhal M, Shieh A, Stolberg A, Ragolia L, Fazzari M & Abrams SA. Free 25(OH)D and calcium absorption, PTH, and markers of bone turnover. Journal of Clinical Endocrinology and Metabolism 2015 100 1410–1415. (https://doi.org/10.1210/jc.2015-25248)

30 Chantily K, He L, Mo J, Jin M, He T, Chen Y, Yang Y, Zhang L & Rong L. Free vitamin D correlates better with bone mineral density and thoracolumbar junction osteoporotic vertebral fractures than serum vitamin D. BMC Musculoskeletal Disorders 2020 21 164. (https://doi.org/10.1186/s12891-020-03179-7)

31 Cavalieri L, Hubbehaher AD, Rousselle O, Bekaert AC, Kovacs S, Vranken L, Peeters S, Le Goff C & Ladang A. Simultaneous measurement of 25(OH)-vitamin D and 24,25(OH)2-vitamin D to define cut-offs for CYP24A1 mutation and vitamin D deficiency in a population of 1200 young subjects. Clinical Chemistry and Laboratory Medicine 2020 58 197–201. (https://doi.org/10.1515/cclm-2019-0996)

32 Schwartz JB, Lai J, Lizaola B, Kane L, Markova S, Weyland P, Terrault NA, Stotland N & Bikle D. A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. Journal of Clinical Endocrinology and Metabolism 2014 99 1631–1637. (https://doi.org/10.1210/jc.2013-3874)

33 Lopez-Molina M, Santillan C, Murillo M, Valls A, Bosch L, Bel J & Granada ML. Measured free 25-hydroxyvitamin D in healthy children and relationship to total 25-hydroxyvitamin D, calculated free 25-hydroxyvitamin D and vitamin D binding protein. Clinical Biochemistry 2018 61 23–27. (https://doi.org/10.1016/j.clbiochem.2018.08.007)

34 Simpson CA, Zhang JH, Vanderschueren D, Fu L, Pennestri TC, Bouillon R, Cole DEC & Carpenter TO. Relationship of total and free 25-hydroxyvitamin D to biomarkers and metabolic indices in healthy children. Journal of Clinical Endocrinology and Metabolism 2020 105 e1631–e1640. (https://doi.org/10.1210/jc.2020-dg230)

Received in final form 15 February 2022
Accepted 25 February 2022
Accepted Manuscript published online 25 February 2022

https://doi.org/10.1530/EC-21-0395
© 2022 The authors Published by Bioscientifica Ltd

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.